SGLT-2 Inhibitors: Are They a Promising Treatment Option in T2DM Patients with NAFLD?
Sodium glucose co-transporter type 2 inhibitors (SGLT-2 inhibitors) are a class of antidiabetics, recently approved for the treatment of patients with T2DM. They feature cardioprotective and renoprotective action, while they exert beneficial effects on metabolic parameters. Non-alcoholic fatty liver...
Main Author: | Dimitrios Patoulias |
---|---|
Format: | Article |
Language: | English |
Published: |
Karolinum Press
2018-04-01
|
Series: | Acta Medica |
Subjects: | |
Online Access: | https://actamedica.lfhk.cuni.cz/60/4/0167/ |
Similar Items
-
SGLT2 inhibitors for treatment of Type 2 diabetes mellitus: Focus on Canagliflozin
by: Santosh Kumar Singh, et al.
Published: (2014-01-01) -
SGLT2 Inhibitors as a Therapeutic Option for Diabetic Nephropathy
by: Daiji Kawanami, et al.
Published: (2017-05-01) -
SGLT2 inhibitors: a promising class of antidiabetic agents
by: Camelia DIACONU
Published: (2018-12-01) -
SGLT-2 inhibitors reduce glucose absorption from peritoneal dialysis solution by suppressing the activity of SGLT-2
by: Ying Zhou, et al.
Published: (2019-01-01) -
Candida sepsis from local infection in a patient with a urostomy on SGLT2 inhibitor therapy
by: Ralph Wendt, et al.
Published: (2020-09-01)